Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Evelo Biosciences, Inc. (EVLO)

1.91   -0.03 (-1.55%) 12-06 09:55
Open: 1.91 Pre. Close: 1.94
High: 2.05 Low: 1.91
Volume: 7,062 Market Cap: 209(M)

Technical analysis

as of: 2022-12-06 9:47:36 AM
Stoxline posted a SELL today, upgraded from strong sell. Downward movement continues, but could change at any time.
Target: Six months: 2.54     One year: 2.8
Support: Support1: 1.83    Support2: 1.52
Resistance: Resistance1: 2.18    Resistance2: 2.4
Pivot: 2.05
Moving Average: MA(5): 2.08     MA(20): 2.04
MA(100): 2.19     MA(250): 2.97
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 35.9     %D(3): 45.8
RSI: RSI(14): 49.9
52-week: High: 8.23  Low: 1.41
Average Vol(K): 3-Month: 156 (K)  10-Days: 68 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ EVLO ] has closed above bottom band by 48.4%. Bollinger Bands are 26.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.21 - 2.23 2.23 - 2.24
Low: 1.85 - 1.86 1.86 - 1.87
Close: 1.92 - 1.94 1.94 - 1.96

Company Description

Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Headline News

Thu, 01 Dec 2022
Evelo Biosciences, Inc. (NASDAQ:EVLO) insiders placed bullish bets worth US$575k in the last 12 months - Yahoo Finance

Mon, 21 Nov 2022
Chardan Capital Comments on Evelo Biosciences, Inc.'s FY2022 Earnings (NASDAQ:EVLO) - MarketBeat

Thu, 17 Nov 2022
Evelo Biosciences Target of Unusually High Options Trading (NASDAQ:EVLO) - MarketBeat

Tue, 15 Nov 2022
Evelo Biosciences Announces Publication of Scientific Basis for SINTAX Medicines in Frontiers in Immunology - Yahoo Finance

Tue, 08 Nov 2022
2022-11-08 | NDAQ:EVLO | Press Release | Evelo Biosciences Inc. - Stockhouse

Mon, 07 Nov 2022
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Evelo Biosciences, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors -

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 110 (M)
Shares Float 57 (M)
% Held by Insiders 1.1 (%)
% Held by Institutions 82.3 (%)
Shares Short 4,450 (K)
Shares Short P.Month 4,550 (K)

Stock Financials

EPS -2.32
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.09
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -70.9
Return on Equity (ttm) -564.3
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.03
Qtrly Earnings Growth 0
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)

Stock Valuations

PE Ratio -0.89
PEG Ratio 0
Price to Book value 22.77
Price to Sales 0
Price to Cash Flow 0

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.